Business
Publication of Annual Report and Notice of AGM
Publication of Annual Report and Notice of AGM.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nPublication of Annual Report 2024 and Notice of 2024 Annual General Meeting\n \nLONDON and NEW YORK, 26 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Annual Report for the year ended 30 June 2024 and the Notice of 2024 Annual General Meeting (\"AGM\") have now been published on the Company's website (https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports and\nhttps://investors.renalytix.com/news-and-events/documents-and-presentations), and posted to shareholders who have not consented to receive electronic communications.\n \nThe AGM will be held in-person on 19 December 2024 at 11.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. \n \nTo help with practical arrangements for the AGM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at [email protected] or by telephone at +44 (0)20 7933 8780.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nStifel (Nominated Adviser, Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nNicholas Moore / Nick Harland / Ben Good\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: 020 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: 07980 541 893 / 07407 804 654\n\n\n\n\n\n\n\n\n\n\n\n\nCapComm Partners\n\n\n\n\n\n\n\nPeter DeNardo\n\n\nTel: 415-389-6400 or [email protected]\n\n\n\n\n \nAbout Renalytix\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment fo...